Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $823.82 +3.10%
Revenue Growth %: +21.1%
Financial Fact:
Net product sales: 857.47M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +21.1%
Financial Fact:
Net product sales: 857.47M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Ryman Hospitality closes $1.38B Grande Lakes Orlando deal
- Everus Construction Group acquires Epsilon Industries for $295M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
